Meg Wood

NYBC Ventures (NYBC Ventures) is a venture capital subsidiary of New York Blood Center Inc founded in 2022. The firm is headquartered in Boston, Massachusetts.

New York Blood Center, Inc. operates blood distribution and research organizations. It provides blood and blood products for transfusions annually. The company was founded in 1964 and is located in New York, NY.

Aronora, Inc. operates as an early clinical stage translational biopharmaceutical company. It researches and develops proprietary biological therapeutics. The company was founded by Andras Gruber and Erik I. Tucker and is headquartered in Portland, OR.

Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation.

Thymmune Therapeutics is a preclinical biotechnology company located in the US that is developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The American company's approach in ipsc-thymic cell manufacturing can generate off-the-shelf cells at scale. Thymmune is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune diseases. The company has strong IP positioning and is backed by early investors and founders of successful high-profile biotechnology companies.

Kalocyte, Inc. operates as a pre-clinical stage healthcare biotech company. It provides artificial red blood cell substitutes used for trauma care related services. The company was founded in 2016 and is headquartered in Baltimore, MD.

Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020.

CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.